Nuvo Research to Discontinue all WF10 [TCDO] Development | BioSpace
***!!!!****"WF10 is an infusion therapy currently approved only in Thailand under the name ****IMMUNOKINE for the treatment of post-radiation-therapy syndromes and adjunctive therapy of diabetic foot ulcers." "Company believes that the results are not sufficient to justify the further development of WF10 for the treatment of allergic rhinitis and plans to discontinue all WF10 development. " "Crescita Therapeutics Inc. (Crescita), will own the Company's existing drug development business"